標(biāo)題: Titlebook: Gene Delivery and Therapy for Neurological Disorders; Xuenong Bo,Joost Verhaagen Book 2015 Springer Science+Business Media New York 2015 A [打印本頁] 作者: Tamoxifen 時(shí)間: 2025-3-21 17:49
書目名稱Gene Delivery and Therapy for Neurological Disorders影響因子(影響力)
書目名稱Gene Delivery and Therapy for Neurological Disorders影響因子(影響力)學(xué)科排名
書目名稱Gene Delivery and Therapy for Neurological Disorders網(wǎng)絡(luò)公開度
書目名稱Gene Delivery and Therapy for Neurological Disorders網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Gene Delivery and Therapy for Neurological Disorders被引頻次
書目名稱Gene Delivery and Therapy for Neurological Disorders被引頻次學(xué)科排名
書目名稱Gene Delivery and Therapy for Neurological Disorders年度引用
書目名稱Gene Delivery and Therapy for Neurological Disorders年度引用學(xué)科排名
書目名稱Gene Delivery and Therapy for Neurological Disorders讀者反饋
書目名稱Gene Delivery and Therapy for Neurological Disorders讀者反饋學(xué)科排名
作者: 值得贊賞 時(shí)間: 2025-3-21 20:20 作者: reception 時(shí)間: 2025-3-22 04:07
,Gene Therapy for Parkinson’s Disease: AAV5-Mediated Delivery of Glial Cell Line-Derived Neurotrophin identified as possible therapeutic molecule for the treatment of neurodegenerative diseases in several different animal models. Delivery of the GDNF has been proven to be very efficient using recombinant AAV vectors. AAV2 has been widely used for the delivery of transgenes to the brain and has eve作者: armistice 時(shí)間: 2025-3-22 06:35
,Gene Delivery and Gene Therapy for Alzheimer’s Disease,efficiently confer long-term expression in a variety of cell types, but innovations including hybrid serotypes, rationally designed capsids, split vectors, specific promoter/enhancer additions, and convection-enhanced delivery have greatly progressed the field of AAV research for neurodegenerative d作者: Communicate 時(shí)間: 2025-3-22 11:48
,Gene Therapy for Huntington’s Disease,psychiatric manifestations. The underlying genetic cause of HD is a mutation in the huntingtin gene resulting in an expanded polyglutamine tract in huntingtin protein that confers a toxic gain of function. Abnormal intranuclear protein inclusions and the progressive degeneration of medium spiny neur作者: 反感 時(shí)間: 2025-3-22 14:05
Gene Therapy Approaches to Promoting Axonal Regeneration After Spinal Cord Injury,nal cord injury and neural repair indicate that the two main obstacles that prevent successful axonal regeneration and functional recovery are the weak intrinsic regenerative capacity of the neurons and the presence of several types of inhibitory molecules in the central nervous system (CNS). Variou作者: 反感 時(shí)間: 2025-3-22 20:00 作者: 硬化 時(shí)間: 2025-3-22 22:39
Targeted Gene Therapy for Ischemic Stroke,re are certain barriers in translating gene-based therapy to the clinical setting. For example, systemic delivery of genes into the brain is prevented by the blood–brain barrier (BBB); intraventricular delivery results in nonspecific distribution and gene expression; and stereotactic injection of ve作者: Keratectomy 時(shí)間: 2025-3-23 03:11 作者: FLIP 時(shí)間: 2025-3-23 06:24 作者: acolyte 時(shí)間: 2025-3-23 13:45
AAV Gene Therapy Strategies for Lysosomal Storage Disorders with Central Nervous System InvolvementLSDs that have central nervous system (CNS) involvement, where enzyme replacement therapy (ERT), the standard of care for LSDs, is ineffective in treating the neurological features of these diseases. Recombinant adeno-associated virus (AAV) vectors have emerged as the most efficient and promising ge作者: 減至最低 時(shí)間: 2025-3-23 16:26
Gene Therapy in Spinal Muscular Atrophy (SMA) Models Using Intracerebroventricular Injection into Ndels of the disease. Preclinical animal studies often proceed to larger animal models and are subsequently incorporated into the final design of the clinical trials. Recent gene therapy advancements with preclinical animal models of spinal muscular atrophy (SMA) have made the move from the bench res作者: COUCH 時(shí)間: 2025-3-23 20:21
Gene Therapy for Chronic Pain: How to Manipulate and Unravel Pain Control Circuits from the Brain?,uring the last decades, the available analgesic drugs remained considerably unchanged. Gene therapy emerged as an important tool in the pain field. Studies in experimental pain models consisted on blockade of nociceptive transmission at the spinal cord by peripheral delivery of viral vectors (mainly作者: GEST 時(shí)間: 2025-3-24 00:00 作者: 重畫只能放棄 時(shí)間: 2025-3-24 04:21
0893-2336 results.Contains key notes and implementation advice from th.This volume aims to explore the latest developments in adeno-associated viral and lentiviral vectors as well as the gene therapy strategies for?the most common neurological disorders, followed by chapters that include step-by-step guides t作者: Awning 時(shí)間: 2025-3-24 08:26
Acute diarrhea in the Dominican Republicdies have demonstrated the efficiency of these vectors both at preclinical and clinical development stages. The current chapter will describe the basic features of AAV vectors, list few examples of their applications as a therapeutic tool to treat diseases of the central nervous system, and discuss progress in the manufacturing process.作者: magnanimity 時(shí)間: 2025-3-24 13:36 作者: 失望未來 時(shí)間: 2025-3-24 18:16
Adeno-Associated Vectors for Gene Delivery to the Nervous System,dies have demonstrated the efficiency of these vectors both at preclinical and clinical development stages. The current chapter will describe the basic features of AAV vectors, list few examples of their applications as a therapeutic tool to treat diseases of the central nervous system, and discuss progress in the manufacturing process.作者: 條街道往前推 時(shí)間: 2025-3-24 21:31
Gene Therapy for Epilepsies,ndidates for epilepsy gene therapy. The techniques described here include adeno-associated viral vector production, genomic titering of the vector, stereotaxic neurosurgery for intracerebral vector administration, and the kainic acid seizure model.作者: 關(guān)節(jié)炎 時(shí)間: 2025-3-25 00:12
Book 2015ost common neurological disorders, followed by chapters that include step-by-step guides to viral vector-based gene delivery in animal models used in the authors’ laboratories. Although safe gene manipulation in neural cells can be achieved, it may still be years away from efficacious gene-based tre作者: Bravado 時(shí)間: 2025-3-25 06:22 作者: 領(lǐng)袖氣質(zhì) 時(shí)間: 2025-3-25 07:41
https://doi.org/10.1007/978-0-387-47672-8y for treating neurological disorders with AAV vectors, with much anticipation for moving these treatments forward to aid patients and families affected by these terrible diseases. In this chapter, we will detail the protocols used for stereotaxic AAV infusion into the brain of mice, cats, sheep, and nonhuman primates.作者: CRAB 時(shí)間: 2025-3-25 11:41 作者: Chemotherapy 時(shí)間: 2025-3-25 17:38 作者: QUAIL 時(shí)間: 2025-3-25 22:15
Child Justice Administration in Africaiency and broad tropism. This chapter discusses lentiviral vectors properties and applications in gene therapy for neurodegenerative diseases, presenting some of the recent progress in this field. We also present the materials and methods necessary to generate high-titer lentiviral vectors. Methods 作者: 細(xì)胞 時(shí)間: 2025-3-26 00:38 作者: 手術(shù)刀 時(shí)間: 2025-3-26 08:14 作者: fluffy 時(shí)間: 2025-3-26 10:24
https://doi.org/10.1007/978-3-319-05071-3ter, we summarize the latest studies on viral vector-mediated gene deliveries in animal models of spinal cord injury. Most of the studies reported so far are aimed at delivery of molecules that prevent cell death, or increase intrinsic regenerating state of injured neurons, or modify the CNS environ作者: muscle-fibers 時(shí)間: 2025-3-26 15:22 作者: 忙碌 時(shí)間: 2025-3-26 19:40
Suitable Families and Parents in Lawistration. This chapter also illustrates the methods of constructing AAV vectors with hypoxia-inducible gene expression, generating the mouse permanent distal middle cerebral artery occlusion (pMCAO) model, standard assays to analyze brain injury and gene transfer, and effective behavior tests for t作者: Celiac-Plexus 時(shí)間: 2025-3-26 21:49 作者: bronchiole 時(shí)間: 2025-3-27 01:25 作者: 廚師 時(shí)間: 2025-3-27 06:03
Protein Deprivation and Offspring Behaviorf pain control circuits of the brainstem to develop strategies to manipulate those areas using HSV-1 vectors. First, we established the dynamics of migration of HSV-1 upon injection into a unique pain facilitatory area of the medulla oblongata (the dorsal reticular nucleus-DRt). At shorter postinjec作者: 下船 時(shí)間: 2025-3-27 12:10 作者: 大約冬季 時(shí)間: 2025-3-27 14:16 作者: 皺痕 時(shí)間: 2025-3-27 20:17
0893-2336 ological Disorders. serves as an ideal guide for researchers attempting to explore the potentials of gene therapy for neurological disorders..978-1-4939-5316-5978-1-4939-2306-9Series ISSN 0893-2336 Series E-ISSN 1940-6045 作者: 具體 時(shí)間: 2025-3-27 22:23 作者: 放縱 時(shí)間: 2025-3-28 04:16 作者: 大量殺死 時(shí)間: 2025-3-28 08:35
,Gene Therapy for Huntington’s Disease,tant huntingtin. More recently, attention has turned to gene silencing or intrabody approaches, powerful approaches that aim to mitigate the pathogenic effects of mutant huntingtin. Promising results have been shown in the evaluation of several of these strategies in rodent and non-human primate mod作者: grudging 時(shí)間: 2025-3-28 13:23 作者: 優(yōu)雅 時(shí)間: 2025-3-28 15:49
Gene Delivery to Neurons of the Dorsal Root Ganglia Using Adeno-Associated Viral Vectors, manipulation of the DRG. However, intrathecal delivery does require much larger amounts of viral stock (10–20 μl) and has the disadvantage that viral particles will leak from the cerebrospinal fluid to the spinal cord and/or peripheral tissues.作者: 小淡水魚 時(shí)間: 2025-3-28 20:10 作者: Fresco 時(shí)間: 2025-3-29 02:49
Adeno-Associated Viral Gene Therapy for Retinal Disorders,lications of gene therapy, concentrating specifically on adeno-associated viral (AAV) vectors, describing the protocols for production and administration of AAV vectors to the eye in the laboratory setting.作者: 左右連貫 時(shí)間: 2025-3-29 05:28 作者: grandiose 時(shí)間: 2025-3-29 08:56 作者: Herpetologist 時(shí)間: 2025-3-29 12:40 作者: 不自然 時(shí)間: 2025-3-29 15:40 作者: 善變 時(shí)間: 2025-3-29 22:38 作者: 演繹 時(shí)間: 2025-3-30 02:27 作者: travail 時(shí)間: 2025-3-30 08:03
Xuenong Bo,Joost VerhaagenIncludes cutting-edge techniques to explore gene therapy for neurological disorders.Provides step-by-step detail essential for reproducible results.Contains key notes and implementation advice from th作者: 現(xiàn)代 時(shí)間: 2025-3-30 08:43
https://doi.org/10.1007/978-1-4939-2306-9Adeno-associated viral vectors; Animal models; Gene expression manipulation; Gene therapy; Gene-based tr作者: 姑姑在炫耀 時(shí)間: 2025-3-30 15:02 作者: 浮雕寶石 時(shí)間: 2025-3-30 18:23
Child Justice Administration in Africaherapy for the nervous system diseases is particularly challenging due to the post-mitotic nature of neuronal cells and the restricted accessibility of the brain itself. Viral vectors based on lentiviruses are particularly attractive vehicles, routinely used in developing gene-based therapies to tre作者: 彩色 時(shí)間: 2025-3-31 00:20
